Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $124.27 Consensus PT from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $124.2727.

Several research analysts have weighed in on DNTH shares. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright increased their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th.

Insider Buying and Selling

In other news, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares in the company, valued at $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marino Garcia sold 166,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the transaction, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 287,084 shares of company stock worth $29,615,923. 3.02% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. ABS Investment Management LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $194,960,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at approximately $32,000. EFG International AG purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at approximately $49,000. Global Retirement Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at approximately $93,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $111.10 on Wednesday. Dianthus Therapeutics has a 52-week low of $22.76 and a 52-week high of $117.88. The business’s 50-day moving average price is $100.75 and its 200 day moving average price is $85.21. The firm has a market cap of $6.07 billion, a P/E ratio of -26.77 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, analysts anticipate that Dianthus Therapeutics will post -3.83 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.